Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite Stable Metastatic Colorectal Cancer

Managements for refractory proficient mismatch repair (pMMR) or microsatellite stable (MSS) metastatic colorectal cancer (mCRC) were still challenging and controversial. Our study sought to investigate the efficacy and safety of anti-PD-1 antibodies plus regorafenib in refractory pMMR/MSS mCRC between July 2019 and June 2021 at the Hunan Cancer Hospital.

难治性错配修复功能完整（proficient mismatch repair，pMMR）或微卫星稳定（microsatellite stable，MSS）的转移性结直肠癌（metastatic colorectal cancer，mCRC）的临床管理仍具挑战性且存在争议。本研究旨在探究2019年7月至2021年6月期间，湖南省肿瘤医院开展的抗PD-1抗体联合瑞戈非尼方案，在难治性pMMR/MSS mCRC患者中的疗效与安全性。